Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 4
A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate coc…
AML (Acute Myeloid Leukemia)GliomaCholangiocarcinoma+1 more
Rigel PharmaceuticalsNCT07486713
Phase 1
Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)
This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduc…
Refractory Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)Relapsed Acute Myeloid Leukemia (AML)+3 more
University of Colorado, DenverNCT07347418